Eli Lilly announced a $5 billion investment in a new Virginia manufacturing facility, its first of four planned US plants totaling at least $27 billion. This facility will focus on producing active ingredients for cancer and autoimmune drugs, particularly antibody drug conjugates. The investment aims to increase domestic production capacity, driven by tax benefits and pipeline growth, creating over 650 new jobs in Virginia and 1800 construction jobs. The plant will utilize advanced technologies and is expected to be operational within five years.

Prepared by Christopher Adams and reviewed by editorial team.